Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > Market Access

Market Access


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Renal Cell Cancer Pricing, Reimbursement, and Access

    $2,995.00

    There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

    August 22, 2018
    Find out more
  • Trends in CNS Dealmaking, 2012–16

    $2,995.00

    Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marketers.

    August 8, 2017
    Find out more
  • Psoriatic Arthritis: Market Access Pricing & Reimbursement

    $2,995.00

    Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market.

    October 17, 2016
    Find out more
  • India Pricing and Reimbursement

    $2,995.00

    Affordability of healthcare is a serious challenge for the majority of the population in India. The lack of properly funded and effective public health services drives a large number of people to receive health services from the private sector.

    November 4, 2016
    Find out more
  • Psoriasis Pricing, Reimbursement, and Access

    $2,995.00

    Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

    March 28, 2019
    Find out more
  • Asthma Pricing, Reimbursement, and Access

    $2,995.00

    The next wave of key therapies in asthma includes biologics, with interleukin (IL)-5 inhibitors first to reach the market.

    October 17, 2016
    Find out more
  • Germany Generics and Biosimilars

    $2,995.00

    The German generics industry is feeling the effects of recent efforts to control drug spending by exerting downward pressure on drug prices.

    November 2, 2016
    Find out more
  • UK Generics and Biosimilars

    $2,995.00

    Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.

    November 2, 2016
    Find out more
  • Key Potential Drug Launches in 2021

    $2,995.00

    As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021.

    1.

    July 24, 2020
    Find out more
  • Orphan Drug Pricing and Reimbursement

    $2,995.00

    Orphan drugs account for a growing portion of payers’ budgets – and comprise some of the most expensive treatments available.

    November 4, 2016
    Find out more
  • 2019 Post-ADA Report

    $2,995.00

    The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

    July 22, 2019
    Find out more
  • Spain Healthcare System and Drug Regulatory Analysis

    $2,995.00

    The market environment in Spain is extremely challenging, with cost-containment measures introduced in 2010–12 contributing to an overall reduction in pharmaceutical spending.

    November 2, 2016
    Find out more
  • First-In-Class Therapies’ Shrinking In-Class Monopolies

    $2,995.00

    Competition from drugs in the same class (with the same mechanism of action and treating the same disease) presents a clear challenge to a first-in-class market entrant. And the speed with which these competitors arrive impacts market dynamics, commercial strategies, and, increasingly, drug prices. Therapies that enjoy extended monopolies as sole entrants in a particular class have greater commercial flexibility in negotiating with payers. Multiple drugs in the same class give payers better leverage with which to negotiate rebates and discounts with drug companies.

    November 15, 2018
    Find out more
  • prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

    Prostate Cancer: Market Access Pricing & Reimbursement

    $2,995.00

    The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

    June 1, 2018
    Find out more
  • Integrated Delivery Networks in the US

    $2,995.00

    Integrated delivery networks (IDNs) are a growing approach to streamlined healthcare in the US, providing support from the cradle to the care home.

    June 27, 2017
    Find out more
  • Indonesia Generics and Biosimilars

    $2,995.00

    In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).

    November 3, 2016
    Find out more
  • Gene Editing: The Next Breakthrough in Regenerative Medicine

    $2,995.00

    Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that could radically change how certain diseases are treated.

    September 1, 2017
    Find out more
  • Japan Pricing and Reimbursement

    $2,995.00

    Pricing and reimbursement processes are closely connected in Japan, with drug pricing largely dependent on innovation. However, achieving premium pricing is difficult, thereby limiting sales potential.

    November 4, 2016
    Find out more
  • Gene Therapy Deal-Making Trends

    Gene Therapy Deal-Making Trends, 2012–17

    $2,995.00

    A robust deal-making market has enabled gene therapy drug development to be advanced and adequately funded through alliances and financings, and in many cases has provided exits for investors through acquisitions.

    February 14, 2018
    Find out more
  • US Regulatory Issues

    $2,995.00

    Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.

    November 2, 2016
    Find out more
  • Biosimilars Market Access in Psoriasis

    $2,995.00

    Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches

    March 6, 2017
    Find out more
  • Value-Based Pricing – Evolution Rather Than Revolution

    $5,000.00

    A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.

    November 4, 2016
    Find out more
  • US Specialty Drug Market Access

    $2,995.00

    High-touch specialty drugs for complex, chronic, high-cost, or rare diseases are an increasingly significant component of the US pharmaceutical market. A sharp growth in regulatory approvals accompanied by high prices has driven rapid increases in expenditure on specialty therapies by both public and private payers.

    November 4, 2016
    Find out more
  • Market Access Trends in Europe

    $3,000.00

    Health technology assessments (HTAs) have become an integral part of procedures employed to inform new drug coverage and pricing decisions across Europe. Methodological approaches to HTA vary, however, while disparities are also apparent in the pertise and financial resources to conduct multidisciplinary assessments, and in the relative weight accorded to recommendations issued by national (or regional) HTA agencies (ICOM, 2017)

    November 16, 2018
    Find out more
  • Managed Entry Agreements

    $2,995.00

    Managed entry agreements (MEAs) describe a range of mechanisms by which pharmaceutical firms and payers share some of the financial and clinical risk associated with the introduction of a new medicine.

    November 4, 2016
    Find out more
  • Key Trends in European Market Access

    $2,995.00

    This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.

    January 26, 2016
    Find out more
  • Access in Emerging Markets: HTA is Making Inroads

    $2,995.00

    Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]

    November 2, 2016
    Find out more
  • 2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

    $2,995.00

    The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications.

    June 13, 2019
    Find out more
  • Key Potential Drug Launches in 2020

    $2,995.00

    As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2020.

    May 28, 2019
    Find out more
  • HER2+ Breast Cancer Pricing and Reimbursement

    $2,995.00

    Despite their high prices, Kadcyla and Perjeta are widely reimbursed in the US and have experienced fast uptake as payers have limited options for cost control in this indication.

    November 4, 2016
    Find out more
Page 2 of 4
Page 2 of 41234
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top